100 years of Festo

The spirit of invention is deeply rooted in our corporate culture. Since our foundation, we have been setting benchmarks by developing innovative solutions that...

Marie Gårdmark: “What to expect from Trump’s second term?”

One may complain about the complex multinational system in EU, but it gives us some predictability that cannot be easily overturned by different member states p...

A tiny animal with great importance

From the mythical Ganges River to the less sacred, but considerably cleaner waters in KI's aquariums in Solna. The little zebrafish has made an unconscious care...

Mercodia AB

Quretech granted a European patent for a new type of antibiotic

The European patent provides protection until 2041. Previously, the patent was granted in China, and the application is currently under review in the USA, India, and Japan.

Life science trends 2025 – The economy

Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to brighter times and fewer bankruptcies. T...

AstraZeneca´s Trixeo approved in the UK using propellant with near-zero Global Warming Potential

AstraZeneca has received approval in the United Kingdom for its inhaled respiratory medicine Trixeo Aerosphere with a new propellant that is reported to reduce ...

Norway rejects national life science strategy – sees no need

The Norwegian Arbeiderpartiet rejects a proposal that Norway should develop its own life science strategy.

Government apoints new experts to medicine and health council

Johanna Fälting, Head of Research at BioArctic, and physician Markus Lingman have been appointed as new members of the Swedish Research Council’s Subject Counci...

ZEISS Lightfield 4D for instant volumetric high-speed imaging

Capturing physiological and neuronal processes in 3D.

Novo Nordisk cuts ties with Hims & Hers after Wegovy dispute

Novo Nordisk is ending its collaboration with Hims & Hers Health due to concerns about the company’s sales and marketing practices related to the weight-loss drug Wegovy.

Drug development booms in Medicon Valley

, but these companies are unknown to people outside the industry despite being the golden vein of the life science sector,” says Anette Steenberg, CEO of the cl...

Security flaw in Swedish breast cancer screening software – woman passed away

A lack of safeguard in Sectra's software led to a woman with breast cancer receiving an incorrect diagnosis. She later passed away. The software is used in 20 o...

LINK Medical recruits Swedish CEO

The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.

Merck KGaA acquires American company in €3.0 billion deal

Germany’s Merck is completing the acquisition of Springwork Therapeutics for 3 billion euros.

Unmatched performance and flexibility in its class

The new ZEISS SPECTRUM family is equipped to be the ideal match from measuring small electronics up to larger housings.

ZEISS introduces the new Smartzoom 100

The future of digital microscopy for efficient optical inspections.

She is CSL Behring's new Nordic General Manager

Since the beginning of january, Helena Bragd is the new Nordic General Manager for the biotech company CSL Behring and CEO of CSL Behring AB.

From powder to implant

Quality assurance for additively manufactured implants.

ZEN core now available for all ZEISS scanning electron microscopes

Introducing intuitive, streamlined SEM control over imaging, analytics, and multi-modal workflows.

ZEISS unveils AI-powered Research Data Platform

Collaboration with Boehringer Ingelheim champions the future of personalized eye care.

Venomaid's rapid test aims to find the right snake bite treatment

Every six seconds, someone on our planet suffers a snake bite, and each time, a race against the clock begins. What kind of snake was it, and which antivenom ca...

Carl Zeiss Meditec achieves revenue growth and stable operating profit

Further recovery in order entry compared to prior year.

Eli Lilly requests re-examination of Alzheimer's drug recommendation

Eli Lilly has requested that the EMA re-examine its opinion on the company's Alzheimer's drug, Kisunla, the agency announced on Friday.